The U.S. Food and Drug Administration (FDA) has agreed to review applications requesting the approval of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for people with advanced renal cell cancer, the most common type of kidney cancer in adults. The applications — requests to extend the indications for Opdivo by Bristol Myers Squibb and Cabometyx by Exelixi — were given priority review status, which accelerates FDA review time from 10 to six months. A decision is expected by Feb. 20, 2021.…
You must be logged in to read/download the full post.
The post Opdivo-Cabometyx Granted FDA Priority Review for Newly Diagnosed Advanced Kidney Cancer appeared first on BioNewsFeeds.